Virtually Painless Blood Sample Collection Device to Revolutionize Diagnostic Testing
|
By LabMedica International staff writers Posted on 07 Nov 2023 |

The discomfort and inconvenience of traditional blood sampling methods like venipuncture and fingersticks, along with a surge in the need for diagnostics that can be performed outside of traditional healthcare settings, have led to the creation of diagnostic tests that only require minimal blood or interstitial fluid volumes. The process of drawing ample amounts of blood using lancets for testing is often a barrier to testing, especially for certain groups of patients. Furthermore, the lack of standardization in fingerstick blood collection, specifically in the techniques of squeezing the finger and the timing of collection and testing, can vary the quality of the blood sample, affecting the test outcomes. Additionally, it's often difficult to gather a substantial volume of blood (at least 200 microliters) from a fingerstick. Now, an innovative method is making the blood collection process more humane, offering benefits for diagnostic and wellness tests administered at clinical labs or at home by patients themselves.
YourBio Health’s (Boston, MA, USA) 'Touch-Activated Phlebotomy' (TAP) is designed for virtually painless whole capillary blood collection using devices incorporating patented technology. The technology overcomes the drawbacks of conventional blood collection by enabling the gathering of a capillary blood sample from any location on the body, eliminating the discomfort caused by fingersticks or traditional phlebotomy. TAP utilizes microneedles finer than an eyelash, making it less painful than both fingerstick methods and venipuncture, as well as other competing devices.
The TAP Micro Select device for blood collection is designed to yield high-quality and high-volume blood samples that are compatible with standard laboratory processing. Having been subjected to testing with hundreds of thousands of patients, this device consistently collects over 200 microliters of blood in more than 92% of attempts. YourBio Health does not perform the tests but owns the patents for these groundbreaking devices. In addition, the company offers a suite of ancillary services like sample tracking, which can be tailored to support a wide array of clinical trials and high-standard blood sampling for wellness purposes. YourBio Health has received further regulatory approval for its TAP Micro Select blood collection device with certification for CE Marking.
"With our patented Halo technology within the TAP micro series of blood collection devices, YourBio Health is unique in offering virtually painless blood sample collection using a bladeless microneedle array. Regulatory approval will enable our device's use with commercial blood collection tubes and allow use in kits that revolutionize blood testing in diagnostics and wellness," said Harry Wilcox, Chief Executive Officer of YourBio Health. "This additional regulatory clearance will further support the trend in decentralized clinical trials and recruitment and maintenance of more diverse patient populations that are known to be more relevant with certain diseases, which will inevitably lead to successes with much needed new treatments, as well as access to treatments for currently underserved and voluntarily unwilling patient groups."
Related Links:
YourBio Health
Latest Pathology News
- FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
- AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
- AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
- PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
- AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
- AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
- Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
- AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
- Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
- Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
- FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
- New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
- EBV Status Helps Predict Survival in Primary CNS Lymphoma
- AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
- Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
- Study Highlights Biomarker Testing Delays in Lung Cancer Care
Channels
Clinical Chemistry
view channel
Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more
Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
Multiple sclerosis (MS) remains difficult to monitor because neurological decline can continue even after relapses stop. This progression independent of relapse activity is often subtle and may escape... Read moreMolecular Diagnostics
view channel
Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read more
Liquid Biopsy Assay Enriches Tumor DNA for Early Detection and Monitoring
Circulating tumor-derived DNA (ctDNA) is often present at very low levels in plasma, making cancer detection and monitoring through liquid biopsy technically challenging. Background cell-free DNA from... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
Lingering symptoms after acute COVID-19 infection remain a clinical challenge, with many patients experiencing fatigue, cognitive problems, and cardiovascular complications months later.... Read more
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read moreMicrobiology
view channel
Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read moreProteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







